Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy

Date

14 Sep 2024

Session

Poster session 10

Topics

Clinical Research;  Translational Research;  Cancer in Adolescents and Young Adults (AYA);  Cancer Registries;  Cancer Intelligence (eHealth, Telehealth Technology, BIG Data)

Tumour Site

Presenters

Hiroaki Ikushima

Citation

Annals of Oncology (2024) 35 (suppl_2): S762-S774. 10.1016/annonc/annonc1599

Authors

H. Ikushima1, K. Watanabe2, A. Shinozaki-Ushiku3, K. Oda3, H. Kage1

Author affiliations

  • 1 Department Of Respiratory Medicine, The University of Tokyo, 113-8655 - Bunkyo-ku/JP
  • 2 Next-generation Precision Medicine Development Laboratory, The University of Tokyo, 113-8655 - Bunkyo-ku/JP
  • 3 Division Of Integrative Genomics, The University of Tokyo, 113-8655 - Bunkyo-ku/JP

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1205P

Background

The probability of discovering mutation-based therapy through comprehensive genomic profiling (CGP) remains low. To enhance the effectiveness and efficiency of precision medicine, it is crucial to identify patients who are likely to benefit from CGP tests. This study aimed to identify characteristics of patients in which mutation-based treatments are discovered by CGP tests.

Methods

We retrospectively analyzed data from 60,655 patients registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which covers 99.7% of cancer patients who have undergone CGP tests in Japan. We developed an eXtreme Gradient Boosting (XGBoost) machine learning model, and used clinical information as input to predict the likelihood of discovering mutation-based drugs through CGP tests. SHapley Additive exPlanations (SHAP) was employed to extract significant features contributing to the model prediction.

Results

The prediction model achieved an area under the receiver operating characteristic curve of 0.819 for the overall cancer population. Positive SHAP values were observed for patients with breast (mean SHAP in breast cancer patients: 1.66), lung (1.19), prostate (0.81), and colorectal (0.17) cancers, while negative SHAP values were associated with pancreatic (-2.40), brain (-1.37), and biliary tract (-0.44) cancers. Positive SHAP values were also associated with the presence of distant metastases and advanced age. Similar trends were observed in cancer type-specific prediction models. Distant metastasis was also associated with discovery of mutation-based therapy in the breast cancer-specific model, even after excluding liquid CGP data. In the adolescent and young adult (AYA) group, brain and bone tumors were associated with negative SHAP values.

Conclusions

Our analysis identified features that predict cases in which mutation-based treatments are discovered by CGP tests, both in the overall cancer population and within specific cancer types and the AYA group. Expedited CGP testing is recommended for patients who match the identified profile to facilitate early targeted therapy interventions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

K. Watanabe, H. Kage: Financial Interests, Institutional, Research Funding: Konica Minolta. K. Oda: Financial Interests, Personal, Advisory Role: Chugai Pharma, Takeda, AstraZeneca/Merck, AstraZeneca, Konica Minolta; Financial Interests, Institutional, Research Funding: AstraZeneca/Merck, Konica Minolta. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.